PHVS (PHVS) Stock Price & Analysis
PHVS (PHVS) rose 0.03% to USD 31.6 as of June 10, 2026 at 05:13 UTC, according to Nexqual real-time market data.
PHVS last closed at USD 31.59; the session ranged USD 30.27–32.17 on volume of 460,635 shares. Market capitalization is $2.21B, with a 52-week range of USD 16–33.33 (NMS). Source: Nexqual, June 10, 2026 at 05:13 UTC.
Key Statistics (as of June 10, 2026 at 05:13 UTC)
| Price | USD 31.6 |
|---|---|
| Change | ▲ 0.03% (up) |
| Previous Close | USD 31.59 |
| Open | USD 31.65 |
| Day Range | USD 30.27 – 32.17 |
| 52-Week Range | USD 16 – 33.33 |
| Volume | 460,635 shares |
| Market Cap | $2.21B |
| Exchange | NMS |
Technical Analysis (PHVS)
Nexqual's technical model rates PHVS "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 05:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.74 (neutral) |
| vs SMA50 | Above (USD 29.34) |
| MACD | 0.41 (positive) |
Analyst Ratings (PHVS)
Wall Street analysts rate PHVS "Strong Buy" based on 13 analysts, with a mean price target of USD 46.25 (range USD 32.55–72.91), per Nexqual as of June 10, 2026 at 05:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 46.25 |
| High Target | USD 72.91 |
| Low Target | USD 32.55 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (PHVS)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.65 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.71 vs est -0.62 ▼ miss |
| 2025-09-30 | USD -0.6 vs est -0.67 ▲ beat |
| 2025-06-30 | USD -0.83 vs est -0.77 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financials & Fundamentals (PHVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -73.02% |
| Debt / Equity | 0.31 |
| Current Ratio | 11.24 |
| Total Cash | $246.96M |
| Total Debt | $738,891 |
| Free Cash Flow | $-87.68M |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Financial Health Score (PHVS)
Nexqual rates PHVS's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $247M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$147M |
| Efficiency | Critical — ROE -73%, ROA -42.3% |
Ownership (PHVS)
| Insider Ownership | +6.14% |
|---|---|
| Institutional Ownership | +85.15% |
| Shares Outstanding | 69.88M |
| Float | 40.09M |
| Short % of Float | +1.23% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Leadership (PHVS)
PHVS is led by Berndt Axel Edvard Modig (age 66), Co-Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 05:13 UTC.
| Co-Founder, CEO & Executive Director | Berndt Axel Edvard Modig (age 66) |
|---|---|
| CFO, Chief Legal Officer & Corporate Secretary | David W. Nassif (age 71) |
| Chief Technology Operations Officer | Stefan Abele (age 55) |
| Director of Corporate Relations | Maryann Cimino |
Major Backers & Investors (PHVS)
Notable institutional backers of PHVS include General Atlantic, L.P., FMR, LLC, Foresite Capital Management IV, LLC, according to Nexqual as of June 10, 2026 at 05:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| General Atlantic, L.P. | 12.28% |
| FMR, LLC | 9.61% |
| Foresite Capital Management IV, LLC | 7.31% |
| venBio Partners LLC | 7.09% |
| Fidelity | 6.47% |
| Viking Global | 5.59% |
| Eqt Fund Management S.a R.l. | 5.24% |
| Deerfield Management Company, L.P | 4.78% |
Source: Nexqual, June 10, 2026 at 05:13 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| IMCR | Immunocore Holdings plc | USD 28.52 | ▲ 0.81% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:13 UTC. This page is informational and not investment advice.